Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

After a dreadful earnings report and conference call, the good times are over for Co-Diagnostics. CODX stock will continue to sink in coming days.

Dump Co-Diagnostics Stock Before It’s Too Late

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -25.00% and 40.82%, respectively, for the quarter ended March 2020.

CoDiagnostics, Inc. (CODX) Reports Q1 Loss, Tops Revenue Estimates

Co-Diagnostics stock has emerged as a big winner from Covid-19. Testing for novel viruses may make it a long-term winner in the new normal.

Co-Diagnostics Stock Is a Buy Ahead of and After Earnings

Co-Diagnostics, Inc. (NASDAQ: CODX) shares are trading volatile on Thursday. Hindenburg Research announced a short position in the stock.

Why Co-Diagnostics Stock Is Moving Today

Another COVID-19 test maker's pain appears to be behind Co-Diagnostics stock's gain.

Why Co-Diagnostics Stock Is Jumping Today

Coronavirus test-maker Co-Diagnostics is on deck to report first-quarter sales of $1 million and a 4-cent per-share loss on Thursday — leading CODX stock to record highs this week.
The post Covid Stock To Watch: Co-Diagnostics Surges To Record Ahead Of Earnings appeared first on Investor's Business Daily.

Covid Stock To Watch: Co-Diagnostics Surges To Record Ahead Of Earnings

CoDiagnostics Inc (CODX) closed at $17.11 in the latest trading session, marking a +0.38% move from the prior day.

CoDiagnostics Inc (CODX) Gains As Market Dips: What You Should Know

This coronavirus testing company's stock has increased 19 times in 2020.

Why Co-Diagnostics Stock Is Up 50% in May After Soaring 49% in April

Co-Diagnostics says its coronavirus tests are 100% accurate in tests in three countries, making CODX stock a smart play.
The post Co-Diagnostics Is a Smart Way to Play Coronavirus Testing appeared first on InvestorPlace.

Co-Diagnostics Is a Smart Way to Play Coronavirus Testing

A no-name investment in 2019, CODX stock has emerged as one of the most relevant players as Covid-19 diagnostics take center stage.
The post Co-Diagnostics Is Becoming More Relevant appeared first on InvestorPlace.

Co-Diagnostics Is Becoming More Relevant

Demand for its coronavirus diagnostic kits could spike in the months ahead.

Approvals and Orders for Co-Diagnostics' COVID-19 Test Kits Are on the Rise

The company announced two new markets for its COVID-19 diagnostics tests.

Why Co-Diagnostics Stock Is Jumping  Today

Co-Diagnostics, Inc. (NASDAQ: CODX) shares are trading higher on Friday, after the company reported its coronavirus test performance data has shown 100% sensitivity and 100% specificity across independent evaluations.

Why Co-Diagnostics Is Trading Higher Today

Co-Diagnostics said Friday its coronavirus test has proven 100% accurate in field testing — leading CODX stock to rocket. Co-Diagnostics sells a test that detects active Covid-19 infection.

Coronavirus Test Maker Soars As Its Diagnostic Proves 100% Accurate

Is  (CODX) Outperforming Other Medical Stocks This Year?

Is Co-Diagnostics (CODX) Stock Outpacing Its Medical Peers This Year?

CODX stock has risen tremendously so far this year. but the company is facing tough competition and has many red flags.

Steer Clear of Co-Diagnostics Stock and Its Multitude of Red Flags

Co-Diagnostics, Inc. (NASDAQ: CODX) shares are trading higher on Thursday. The company announced that OralDNA Labs, a CLIA-certified laboratory, have validated a COVID-19 PCR test based on the company's patented CoPrimer technology for use with saline oral rinse samples.

Why Co-Diagnostics Stock Is Trading Higher Today

The company's COVID-19 test received a key validation.

Why Co-Diagnostics Stock Is Soaring 15.5% Higher Today

Co-Diagnostics Inc. (NASDAQ: CODX) has been the toast of Wall Street after it went from penny stock status to a revered coronavirus testing stock.

With FDA Approval in Place, Is Co-Diagnostics Stock Already Fully Priced?

Many companies are vying to deliver the best coronavirus test. Co-Diagnostics is unlikely to be the ultimate winner in a crowded marketplace.

When It Comes to Coronavirus Investing, CODX Stock Is a Bad Bet

A fresh FDA approval means that CODX stock has full permission to clear its previous high mark.
The post Testing-Kit Clearance Is the Green Light to Buy Co-Diagnostics appeared first on InvestorPlace.

Testing-Kit Clearance Is the Green Light to Buy Co-Diagnostics

Establishment Labs Holdings Inc

Novocure

OncoCyte

Medical Services Outlook Bright Amid Coronavirus Crisis

Co-Diagnostics Inc. (NASDAQ: CODX) shares popped on Monday after the company announced a key update from the U.S.

Why This FDA Update Is Huge for Co-Diagnostics

Is Co-Diagnostics (CODX) Outperforming Other Medical Stocks This Year?

Co-Diagnostics Inc (NASDAQ: CODX) shares are getting boost on Monday. The positive reaction is in the wake of an announcement from the company that its Logix Smart Coronavirus COVID-19 Test has received Emergency Use Authorization from the U.S.

News for Co-Diagnostics Stock (CODX)